Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma

Pashna N. Munshi, Yue Chen, Kwang W. Ahn, Farrukh T. Awan, Amanda Cashen, Geoffrey Shouse, Mazyar Shadman, Paul Shaughnessy, Joanna Zurko, Frederick L. Locke, Aaron M. Goodman, Jose C.Villaboas Bisneto, Craig Sauter, Mohamad A. Kharfan-Dabaja, Gabrielle Meyers, Samantha Jaglowski, Alex Herrera, Mehdi Hamadani

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Data for outcomes after autologous hematopoietic cell transplantation (auto-HCT) in diffuse large B-cell lymphoma (DLBCL) patients ≥70 years are limited. Auto-HCT is feasible in older DLBCL patients. Using the Center for International Blood and Marrow Transplant Research database, we compared outcomes of auto-HCT in DLBCL patients aged 60 to 69 years (n = 363) versus ≥70 years (n = 103) between 2008 and 2019. Non-relapse mortality (NRM), relapse/progression (REL), progression-free survival (PFS), and overall survival (OS) were modeled using Cox proportional hazards models. All patients received BEAM conditioning (carmustine, etoposide, cytosine arabinoside and melphalan). On univariate analysis, in the 60 to 69 years versus ≥70 years cohorts, 100-day NRM was 3% versus 4%, 5-year REL was 47% versus 45%, 5-year PFS 40% versus 38% and 5-year OS 55% versus 41%, respectively. On multivariate analysis, patients ≥70 had no significant difference in NRM (hazard ratio [HR] 1.43, 95% confidence interval [CI] 0.85-2.39), REL (HR 1.11, 95% CI 0.79-1.56), PFS (HR 1.23, 95% CI 0.92-1.63) compared to patients 60 to 69 years. Patients ≥70 years had a higher mortality (HR 1.39, 95% CI 1.05-1.85, p=0.02), likely because of inferior post-relapse OS in this cohort (HR 1.82, 95% CI 1.27-2.61, P = .001). DLBCL was the major cause of death in both cohorts (62% versus 59%). Older patients should not be denied auto-HCT solely on the basis of chronological age.

Original languageEnglish
Pages (from-to)487.e1-487.e7
JournalTransplantation and Cellular Therapy
Issue number8
StatePublished - Aug 2022


  • Autologous transplant
  • BEAM
  • Diffuse large B cell lymphoma
  • Older
  • Relapse


Dive into the research topics of 'Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma'. Together they form a unique fingerprint.

Cite this